patients

FINANCIAL REPORT
3 STOCKS OF DRUGS
In 2015, DNDi purchased vials of SSG, lipossomal amphotericin B
(Ambisome ® ), paromomycin, and caps of miltefosine 10mg and
50mg at an estimated value of EUR 154,357 from various partners
(MSF Logistique, MSF supply, IDA Foundation), for use in the routine
VL patient management and on-going VL clinical trials (HIV/VL
co-infection study and Miltefosine Allometric Study). Stocks of SSG,
AmBisome ® , miltefosine, and paromomycin at an estimated value
of EUR 156,537 are stored at clinical trial sites in Ethiopia, Kenya,
Sudan, and Uganda.The stock held in India in 2014 was donated to
the Indian Ministry of Health in 2015.
2014 Quantity Vials Quantity Caps
Countries / drugs SSG (1) AmBisome ® (2) 50mg
Paromomycin Miltefosine
Miltefosine
10mg
Total in EUR
India 2,895 13,050 15,894 38,022 107,496
Ethiopia 500 1,839 3,000 2,300 - 34,546
Kenya 1,070 128 4,060 - - 13,342
Sudan 1,000 160 930 - - 10,170
Uganda 650 140 1,100 - - 7,610
Total vials/caps 3,220 5,162,00 22,140 18,194 38,022
Total in EUR 22,540 72,268 22,140 18,194 38,022 173,164
(1) SSG Cost per vial = EUR 7; (2) AmBisome ® Cost per vial = EUR 14; paromomycin & miltefosine are valued at EUR 1 per unit
2015 Quantity Vials Quantity Caps
Countries / drugs SSG (1) AmBisome ® (2) 50mg
Paromomycin Miltefosine
Miltefosine
10mg
Total in EUR
India - - - - -
Ethiopia 4,367 555 2,150 - - 38,342
Kenya 4,769 1,726 4,620 3,150 3,822 71,274
Sudan 1,825 835 2,105 - - 28,085
Uganda 800 541 700 840 2,758 18,836
Total vials/caps 11,761 3,657 9,575 3,990 6,580 -
Total in EUR 70,566 65,826 9,575 3,990 6,580 156,537
(1) SSG Cost per vial = EUR 6; (2) AmBisome ® Cost per vial = EUR 18; paromomycin & miltefosine are valued at EUR 1 per unit
76 › DNDi Annual Report 2015